Appointment dossier — Uterine Leiomyosarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Uterine Leiomyosarcoma
- Cisplatin — Human evidence · 1 positive · PMID 37143137
- Olaparib — Human evidence · 1 positive · PMID 37143137
- Trastuzumab Deruxtecan — Human evidence · 1 positive · PMID 39639215
- Trastuzumab-Deruxtecan (T-Dxd) — Human evidence · 1 positive · PMID 39639215
- Docetaxel — Review evidence · 1 positive / 1 negative-mixed · PMID 37158392, 24840518
- Gemcitabine — Review evidence · 1 positive · PMID 37158392
- Resveratrol — Review evidence · 1 positive · PMID 28935150
- Bevacizumab — Review evidence · 0 positive · PMID 29759566
- Dacarbazine — Review evidence · 0 positive / 1 negative-mixed · PMID 24840518
- Doxorubicin — Review evidence · 0 positive / 1 negative-mixed · PMID 24840518
- Ifosfamide — Review evidence · 0 positive / 1 negative-mixed · PMID 24840518
- Nivolumab †Rx — Review evidence · 0 positive / 1 negative-mixed · PMID 30244960
- Pembrolizumab — Review evidence · 0 positive / 1 negative-mixed · PMID 30244960
- Selenium (Stand-alone) — Review evidence · 0 positive / 1 negative-mixed · PMID 33401525
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05649956 · Phase 2 — Letrozole in Uterine Leiomyosarcoma (United States)
- NCT06524583 · Phase 2 — Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour (France)
- NCT07467772 · Phase 2 — Ph 2 Elacestrant in ER Positive Uterine Sarcomas (United States)
- NCT07076186 · Phase 2 — Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS (United States)
- NCT01793168 — Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (United States)
- NCT06851663 · Phase 2 / Phase 3 — Trop2-targeted immunoPET Imaging of Solid Tumors (China)
- NCT05208762 · Phase 1 — A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (United States)
- NCT06584032 · Phase 3 — Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer (China)
- NCT07298642 · Phase 2 / Phase 3 — Extended-field Proton Therapy for Cervical Cancer (Taiwan)
- NCT06277154 · Phase 2 — MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (China)
- NCT06481592 · Phase 2 — A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. (United States)
- NCT07055399 · Phase 2 — Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) (China)
- NCT07647198 · Phase 2 — FATIMA Trial: EGCG and Vitamin D3 for Prevention of Fibroid Recurrence (United Arab Emirates)
- NCT06522828 · Phase 2 — A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients (China)
- NCT06289751 · Phase 2 — Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer (China)
- NCT06023862 · Phase 2 — A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (Australia)
- NCT07643012 — Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer (United States)
- NCT05977621 — Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle Tracking (United States)
Most-relevant first: trials that name Uterine Leiomyosarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Nivolumab †Rx × immunosuppressants (high-stakes) — Avoid (high)
- Resveratrol × anticoagulants (high-stakes) — Monitor (moderate)
- Resveratrol × CYP3A4 substrates (high-stakes) — Monitor (low)
- Selenium (Stand-alone) × platinum_chemo (high-stakes) — Monitor (low)
- Nivolumab †Rx × Ipilimumab — Synergize (moderate)
- Nivolumab †Rx × corticosteroids — Use For IrAE (low)
- Resveratrol × Doxorubicin — Synergize (low)
- Selenium (Stand-alone) × antioxidants — Synergize (low)
- Selenium (Stand-alone) × Cisplatin — Synergize (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Cisplatin has been studied in people for Uterine Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Olaparib has been studied in people for Uterine Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Trastuzumab Deruxtecan has been studied in people for Uterine Leiomyosarcoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05649956), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?